INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 145 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.94 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,240,126 | +123.8% | 1,037,763 | +33.5% | 0.07% | +124.2% |
| Q2 2023 | $8,598,066 | +86951.4% | 777,402 | +5.7% | 0.03% | -21.4% |
| Q1 2023 | $9,877 | +41.3% | 735,488 | +30.1% | 0.04% | +20.0% |
| Q4 2022 | $6,991 | -99.9% | 565,185 | +5.3% | 0.04% | -10.3% |
| Q3 2022 | $7,487,000 | +4.3% | 536,764 | +3.3% | 0.04% | +2.6% |
| Q2 2022 | $7,177,000 | -9.8% | 519,722 | +6.2% | 0.04% | 0.0% |
| Q1 2022 | $7,961,000 | +25.8% | 489,352 | +26.0% | 0.04% | +26.7% |
| Q4 2021 | $6,326,000 | +26.4% | 388,350 | +15.2% | 0.03% | +15.4% |
| Q3 2021 | $5,006,000 | +40.5% | 337,141 | +88.9% | 0.03% | +30.0% |
| Q2 2021 | $3,564,000 | +89000.0% | 178,488 | +89144.0% | 0.02% | – |
| Q1 2021 | $4,000 | 0.0% | 200 | 0.0% | 0.00% | – |
| Q4 2020 | $4,000 | -50.0% | 200 | 0.0% | 0.00% | – |
| Q3 2020 | $8,000 | -20.0% | 200 | 0.0% | 0.00% | – |
| Q2 2020 | $10,000 | -23.1% | 200 | 0.0% | 0.00% | – |
| Q1 2020 | $13,000 | – | 200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |